Whalesbook
India's stock market rose on April 29, 2026, strongly driven by a good fourth-quarter earnings season. However, this overall gain hides sector shifts and persistent challenges that could affect future growth.
Earnings Drive Mixed Market Gains
The Nifty 50 gained 0.76% to close at 24,177.65, and the Sensex rose 0.79% to 77,496.36. This broad market uptick was initially supported by widespread buying. However, profit-taking occurred at higher levels, trimming some intraday gains. Sector performance was mixed: Auto, IT, FMCG, and Realty indices rose about 1%, while infrastructure, metal, oil & gas, and pharma sectors added roughly 0.5%. Conversely, PSU banks, media, and consumer durables dipped. Stocks like Maruti Suzuki India, Coal India, and ITC Limited were among the top index gainers.
Sector Shifts and Stock-Specific Performance
The mixed sectoral performance suggests a market driven by specific catalysts rather than uniform optimism. Bandhan Bank surged approximately 11% after reporting a 68% year-on-year increase in its fourth-quarter net profit to ₹534.14 crore. This profit jump was mainly driven by significantly lower funds set aside for potential losses. However, concerns about shrinking profit margins and elevated bad loans (GNPAs) at 3.27% remain. CEAT shares climbed after a 145% surge in net profit to ₹243.85 crore on revenues up 23%. Greenply Industries reported an 86.75% profit increase in Q4 FY26 to ₹31 crore, driven by strong volume growth. Star Health and Allied Insurance Company's net profit rose to ₹111 crore, aided by better underwriting and a lower loss ratio. Vedanta posted an 88% jump in Q4 net profit to ₹9,352 crore. On the regulatory front, Solara Active Pharma Sciences gained 2.5% after the U.S. FDA classified its Puducherry facility with a status indicating procedural improvements are needed, rather than major violations.
Valuation Concerns and Peer Comparisons
Despite positive earnings, the valuations of some leading gainers warrant scrutiny. Bandhan Bank, even with its profit surge, trades at a Price-to-Earnings (P/E) ratio of approximately 27-29x as of late April 2026, significantly higher than peers like HDFC Bank (15.25x) and ICICI Bank (16.48x). Its P/E of 20.53, coupled with a low return on equity (ROE) of around 5% for FY26, suggests potential overvaluation compared to industry standards. In the metals sector, Vedanta operates within an industry P/E of about 22.6x, with companies like Hindalco Industries trading at 14.7x and Hindustan Zinc at 19.2x. The Indian pharmaceutical sector has an average P/E of around 29x, with Dr. Reddy's Laboratories at 18.1x and Sun Pharmaceuticals at 37.3x.
Macroeconomic Factors and Investor Flows
The market's performance is occurring against ongoing economic challenges. Foreign Institutional Investors (FIIs) continued their selling streak in April 2026, pulling out approximately ₹39,224.10 crore as of April 20, 2026, and ₹43,967 crore for the month according to NSDL data. This selling is notable, especially following record outflows in March 2026. While Domestic Institutional Investors (DIIs) have provided a counter-balance by investing significant capital, sustained foreign selling indicates underlying global risk aversion. Geopolitical tensions, including developments between the U.S. and Iran, and volatility in crude oil prices, continue to influence investor sentiment. Historically, periods of geopolitical uncertainty have led to increased market volatility and potential for profit-taking.
Historical Context: Resilience Tested
Looking back to April 2025, the market saw a strong overall gain for the Nifty 50, driven by foreign portfolio investor (FPI) inflows and robust corporate earnings. However, it also experienced brief volatility due to geopolitical events. The current situation, however, involves steady foreign selling and higher geopolitical risk, suggesting the market's current strength may be tested.
Key Concerns
Bandhan Bank: Valuation and Margin Pressures
Although Bandhan Bank's profit jumped, its valuation raises concerns. A P/E ratio around 27-29x for late April 2026, significantly higher than its larger private banking peers, suggests the market is pricing in considerable future growth that may be challenging to achieve given existing pressures. The net interest margin (NIM) has compressed year-on-year. Although the bank aims to increase its secured loan book and deposits that cost little (CASA ratio), its return on equity (ROE) of approximately 5% for FY26 lags significantly behind industry standards. A key challenge for the bank will be growing its loan book 2-3% faster than the industry while managing credit costs and shrinking profit margins.
Solara Active Pharma's Regulatory Status
Solara Active Pharma Sciences received a classification from the U.S. FDA for its Puducherry facility that indicates procedural improvements are needed. While this is a positive step, it shows the FDA found areas for the company to address. The company operates alongside competitors like Divi's Laboratories and Laurus Labs, who are also subject to stringent regulatory oversight. A VAI status is a step in the right direction, but sustained compliance and absence of further observations will be critical for long-term investor confidence.
Broader Market Risks
The sustained FII outflows, coupled with elevated crude oil prices and ongoing geopolitical tensions, present significant risks to the broader market. Given foreign selling and economic uncertainties, current market price-to-earnings (P/E) levels suggest a possible correction if earnings growth slows or geopolitical risks rise. The nearly 160 stocks that touched 52-week highs on the BSE might be susceptible to profit-taking if broader market sentiment deteriorates.
The Outlook
Analyst sentiment remains divided for some of the featured stocks. JM Financial maintains an 'Add' rating on Bandhan Bank with a raised target price of ₹200, implying a 25% upside, citing an attractive price-to-book value. However, this optimism is tempered by the bank's lagging ROE and persistent margin concerns. Motilal Oswal Financial Services holds a 'Buy' rating on Star Health, noting strong premium growth and an improving combined ratio. Conversely, IIFL downgraded CEAT to 'Add' from 'Buy', indicating a more cautious stance despite strong quarterly results. The market's direction will likely depend on the trajectory of global geopolitical events, the sustainability of domestic institutional inflows, and the ability of companies to navigate rising input costs and margin pressures through effective pricing and cost management strategies.